Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations.
Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations.
复制标题
DOI：
10.1007/s00270-011-0287-7
复制
发表时间：
2012-10
影响因子：
2.9
通讯作者：
Geschwind, Jean-Francois H.
中科院分区：
文献类型：
--
作者：
Lencioni, Riccardo;de Baere, Thierry;Burrel, Marta;Caridi, James G.;Lammer, Johannes;Malagari, Katerina;Martin, Robert C. G.;O'Grady, Elizabeth;Isabel Real, Maria;Vogl, Thomas J.;Watkinson, Anthony;Geschwind, Jean-Francois H.
通过对随机对照试验的荟萃分析，经动脉化疗栓塞（TACE）已被确立为孤立于肝脏且肝功能保留的大型或多结节非浸润性肝细胞癌（HCC）非手术患者的标准治疗。虽然常规TACE联合给予抗癌油乳剂和栓塞剂是最流行的技术，但栓塞药物洗脱珠的引入为基于阿曲朵多的方案提供了替代方案。实验研究表明，药物洗脱珠的TACE具有安全的药代动力学特征，并在动物模型中有效杀死肿瘤。早期的临床经验已经证实，药物洗脱珠粒提供局部缺血和细胞毒性效应的组合，全身毒性暴露较低。最近，随机对照试验显示了使用载有阿霉素的栓塞微球DC Bead（DEBDOX;药物洗脱珠阿霉素）进行TACE方案的临床价值。传统TACE的一个重要局限性是技术和治疗方案的不一致性。这种局限性阻碍了TACE作为标准肿瘤治疗的接受。载多柔比星的DC Bead提供了传统TACE无法提供的一致性和可重复性水平，并提供了实施标准化HCC治疗方法的机会。考虑到这一点，一个医生小组参加了在佛罗伦萨，意大利欧洲介入肿瘤学会议期间举行的共识会议，以制定一套关于DEBDOX在HCC治疗中使用的技术建议。专家小组的结论摘要如下。
Tranarterial chemoembolization (TACE) has been established by a meta-analysis of randomized controlled trials as the standard of care for nonsurgical patients with large or multinodular noninvasive hepatocellular carcinoma (HCC) isolated to the liver and with preserved liver function. Although conventional TACE with administration of an anticancer-in-oil emulsion followed by embolic agents has been the most popular technique, the introduction of embolic drug-eluting beads has provided an alternative to lipiodol-based regimens. Experimental studies have shown that TACE with drug-eluting beads has a safe pharmacokinetic profile and results in effective tumor killing in animal models. Early clinical experiences have confirmed that drug-eluting beads provide a combined ischemic and cytotoxic effect locally with low systemic toxic exposure. Recently, the clinical value of a TACE protocol performed by using the embolic microsphere DC Bead loaded with doxorubicin (DEBDOX; drug-eluting bead doxorubicin) has been shown by randomized controlled trials. An important limitation of conventional TACE has been the inconsistency in the technique and the treatment schedules. This limitation has hampered the acceptance of TACE as a standard oncology treatment. Doxorubicin-loaded DC Bead provides levels of consistency and repeatability not available with conventional TACE and offers the opportunity to implement a standardized approach to HCC treatment. With this in mind, a panel of physicians took part in a consensus meeting held during the European Conference on Interventional Oncology in Florence, Italy, to develop a set of technical recommendations for the use of DEBDOX in HCC treatment. The conclusions of the expert panel are summarized.
登录
查看更多内容
影响因子：
2.9
作者：
Lee, Kwang-Hun;Liapi, Eleni;Vossen, Josephina A.;Buijs, Manon;Ventura, Veronica Prieto;Georgiades, Christos;Hong, Kelvin;Kamel, Ihab;Torbenson, Michael S.;Geschwind, Jean-Francois H.
通讯作者：
Geschwind, Jean-Francois H.
影响因子：
2.9
作者：
Grosso, Maurizio;Vignali, Claudio;Sarti, Ilaria
通讯作者：
Sarti, Ilaria
DOI：
10.1016/j.jvir.2009.10.038
发表时间：
2010-03-01
影响因子：
2.9
作者：
Nicolini, Antonio;Martinetti, Laura;Sangiovanni, Angelo
通讯作者：
Sangiovanni, Angelo
DOI：
10.1016/j.jvir.2009.03.036
发表时间：
2009-07-01
影响因子：
2.9
作者：
Kim, Hyo-Cheol;Chung, Jin Wook;Jae, Hwan Jun
通讯作者：
Jae, Hwan Jun
英国的癌症死亡率：2025年的预测。
影响因子：
8.8
作者：
Olsen, A. H.;Parkin, D. M.;Sasieni, P.
通讯作者：
Sasieni, P.